MOTS-c: Compound Profile

For most of the last century the mitochondrial genome was thought to encode exactly thirty-seven gene products: thirteen proteins of the electron-transport chain, twenty-two transfer RNAs, and two ribosomal RNAs. MOTS-c is one of a small handful of peptides that broke that count. It is encoded inside the 12S rRNA region of mitochondrial DNA, was identified in 2015 by Lee, Cohen, and colleagues at the University of Southern California, and is now considered a founding member of the mitochondrial-derived peptide (MDP) class^[1][4]. The biology is genuinely novel; the human data is mostly observational; the closest the molecule has come to a controlled clinical readout was a Phase 1 program of a synthetic analogue that was discontinued. This profile describes the molecule the way the primary literature actually describes it.

Nothing in this article is a recommendation. MOTS-c is supplied by PepMax under the product slug mots-c for laboratory research use only. It is not approved by FDA, EMA, MHRA, Health Canada, or any other regulator we ship to for human or veterinary therapeutic use.

At a glance

The data sheet below summarizes molecular identity. Sequence, formula, and the genomic origin come from the original 2015 characterization paper and subsequent mechanism work.

What MOTS-c is

MOTS-c — Mitochondrial Open reading frame of the Twelve S rRNA type-c— is a 16-amino-acid peptide whose coding sequence sits inside the MT-RNR1 gene of the mitochondrial genome. MT-RNR1 is the gene for the small (12S) mitochondrial ribosomal RNA; for decades it was annotated only as a structural RNA component of the mitochondrial ribosome. The 2015 paper by Lee and colleagues showed that a short open reading frame within MT-RNR1 produces a translated, secreted, biologically active peptide that circulates in plasma and acts on tissues other than the mitochondrion that encoded it^[1].

Three properties of the molecule shape how the rest of the literature reads. First, it is mitochondrially encoded: the gene is on the maternally inherited mitochondrial chromosome rather than the nuclear genome, which is unusual for a secreted peptide and which means natural genetic variation in MOTS-c follows mitochondrial haplogroup inheritance rather than Mendelian segregation. Second, it is short and unmodified: 16 residues, no disulfide, no glycosylation, with a molecular weight near 2.2 kDa, which makes synthesis and chemical characterization straightforward but also means systemic half-life is short. Third, it is a retrograde signal: the prevailing mechanistic interpretation is that MOTS-c communicates information about mitochondrial state — metabolic stress, nutrient availability — back to the nucleus, modulating nuclear gene expression in response^[2].

Proposed mechanisms

Two mechanistic axes dominate the MOTS-c literature: AMPK activation through the folate cycle, and stress-induced nuclear translocation with direct effects on gene expression. They are not independent — AMPK is reported both upstream and downstream of the nuclear event — and the field treats them as two facets of a coordinated metabolic response.

AMPK activation via the folate cycle

The 2015 Lee paper proposed and tested a mechanism in which MOTS-c inhibits the methylene- tetrahydrofolate-dependent step of the folate cycle, blocking de novo purine biosynthesis and producing accumulation of AICAR (5-aminoimidazole-4-carboxamide ribonucleotide). AICAR is a well-characterized AMPK activator, and AMPK activation is the proximate readout that the paper consistently observed across skeletal muscle, adipose, and hepatocyte models^[1]. Downstream of AMPK, the predicted metabolic consequences — increased glucose uptake, suppressed hepatic gluconeogenesis, attenuated lipogenesis — track the patterns reported in the obesity and insulin-resistance experiments.

Nuclear translocation

The 2018 Kim et al. paper described a second mechanistic axis: under metabolic stress (glucose restriction, oxidative stress), MOTS-c translocates from the cytoplasm to the nucleus within approximately one hour and modulates expression of stress-response and antioxidant-response genes^[2]. The authors reported that AMPK activity is required for the translocation and that the nuclear MOTS-c associates with chromatin at promoters of NRF2-axis and broader stress-response targets. The proposed framework is a positive feedback loop: metabolic stress drives translocation, translocation drives gene- expression remodeling, and the program supports AMPK signaling that further promotes translocation.

Mitochondrial-to-nuclear retrograde signaling

Both axes are interpreted in the broader literature as instances of retrograde signaling— communication from mitochondria back to the nucleus that adjusts nuclear-encoded responses to mitochondrial state. The conceptual framing matters: it distinguishes MOTS-c (and the MDP class generally) from peptide hormones with cell-surface receptors, and it predicts that effects should be most prominent when mitochondrial function is challenged or when energy demand is elevated. The reported pattern of MOTS-c action under fasting, exercise, and metabolic stress is consistent with that prediction^[3][4].

Evidence map

The figure below summarizes the published MOTS-c evidence base by domain. Each row reflects the highest level of evidence we have identified from peer-reviewed sources, not the volume of studies. Where evidence is limited to in vitro, animal, or human-observational models, that is stated explicitly.

Glucose, insulin, and obesity models

The 2015 Cell Metabolism paper is the anchor of the metabolic literature^[1]. In high-fat-diet mouse models, intraperitoneal MOTS-c attenuated diet-induced obesity, improved fasting insulin and glucose handling, and reduced hepatic steatosis. In cultured myocytes, adipocytes, and hepatocytes, MOTS-c increased glucose uptake in an AMPK-dependent manner and shifted fuel-utilization markers toward fatty-acid oxidation. The pattern is broadly consistent with what would be predicted from sustained low-grade AMPK activation, and is the framing that motivated the CohBar metabolic-disease clinical program.

Skeletal muscle and exercise

The Reynolds et al. 2021 paper in Nature Communications is the most substantive recent primary work and the source of the “exercise peptide” framing^[3]. The study reported that MOTS-c expression and circulating levels rise acutely with exercise in both mice and humans, that exogenous MOTS-c administration improved running performance and physical function in aged mice, and that genetic loss of MOTS-c attenuates the normal exercise-adaptation response. Two interpretive cautions belong here. First, the human data in this paper are circulating-peptide measurements before and after acute exercise, not an interventional trial. Second, “exercise mimetic” is the secondary-literature framing; the primary paper is more careful and frames MOTS-c as required for the normal adaptive response, not a substitute for exercise itself.

Aging and longevity-association data

Two complementary observations anchor the aging literature. Cobb et al. 2016 reported that circulating MOTS-c declines with age in human plasma cohorts and that several MDPs covary with markers of insulin sensitivity and inflammation^[6]. Fuku et al. 2015 reported that the m.1382A>C polymorphism in the MOTS-c coding region (which alters the peptide sequence at residue 14) was over-represented in Japanese male centenarians relative to younger Japanese controls^[5]. The polymorphism analysis is a case-control population-genetics study; it is hypothesis-generating rather than confirmatory of a longevity mechanism, and the effect was sex-specific in the original report.

Nuclear translocation and gene expression

Kim et al. 2018 is the central paper for the retrograde-signaling mechanism^[2]. Using fractionation, immunofluorescence, and ChIP-seq, the authors reported that under glucose restriction or oxidative challenge, MOTS-c localizes to the nucleus, associates with chromatin, and modulates expression of stress-response and antioxidant programs that overlap substantially with NRF2-axis targets. The framework reframes MOTS-c not as a circulating hormone with a receptor but as a peptide that physically participates in the transcriptional response of the nucleus to mitochondrial state. The paper is a single-laboratory primary report; broad independent replication of the chromatin-engagement component is still developing.

Human data and the CB4211 program

Human evidence for native MOTS-c is currently limited to observational measurements: circulating peptide levels in plasma cohorts (declining with age, increasing with acute exercise), polymorphism distributions across populations, and correlations with metabolic and inflammatory markers. There is no published controlled efficacy trial of native MOTS-c in humans.

The closest the molecule has come to a controlled clinical readout is the CohBar CB4211 program. CB4211 was a synthetic peptide analogue derived from MOTS-c, designed for improved drug-like properties (chiefly half-life). CohBar registered a Phase 1a/1b study in subjects with non-alcoholic fatty liver disease and obesity (NCT04004273)^[9]. The program was discontinued in 2021 after the company concluded the trial data did not support continued development; CohBar subsequently wound down operations in 2023. There is no peer-reviewed efficacy publication from the trial. Importantly, CB4211 is not the same molecule as native MOTS-c, and the program’s outcome cannot be read either as validation or refutation of the native sequence’s biology.

Research timeline

Limitations of the evidence base

Read together, the MOTS-c literature describes a genuinely novel biology — a functional peptide encoded inside a gene previously thought to be RNA-only — with a coherent set of mechanistic claims that have been replicated in part across laboratories. Read critically, it has limits that any researcher evaluating the molecule should understand explicitly.

• Originator concentration.A large fraction of the primary literature — the discovery paper, the nuclear-translocation paper, the exercise paper, and several mechanism follow-ups — comes from the Lee/Cohen group at USC and close collaborators. The framework is consistent within that body of work; independent replication of specific findings (especially the chromatin-engagement component) is more limited. This is structurally similar to the Sikirić/BPC-157 and Pickart/GHK-Cu situations and warrants the same critical posture.
• Mechanism-by-association. The folate-cycle / AICAR / AMPK chain is coherent and supported by metabolite measurements in cell systems. Whether AMPK activation in tissues at physiological circulating concentrations of MOTS-c quantitatively accounts for the in vivo phenotypes is a separate question; most in vivo studies use exogenous, supraphysiological dosing.
• Human evidence is observational. Circulating peptide measurements, age-correlation data, and polymorphism associations are hypothesis-generating. They are not controlled efficacy data. The Japanese centenarian polymorphism finding in particular is a case-control association in one population; broader replication and mechanistic linkage are still developing.
• The closest clinical readout was an analogue, not the native peptide. CB4211 differs from native MOTS-c. The Phase 1 program’s discontinuation cannot be read either as validating or as refuting the native sequence; it is a data point about one analogue at one set of doses in one indication.
• Pharmacokinetics in humans are not characterized. Plasma half-life, tissue distribution, and metabolic fate of injected native MOTS-c in humans are not described in peer-reviewed literature. The native sequence has properties (short length, rapid aminopeptidase clearance) that motivated the CB4211 analogue program in the first place.
• “Exercise mimetic” is secondary-literature framing. The primary papers describe MOTS-c as required for normal exercise adaptation and as inducible by exercise, not as a substitute for exercise. Translating the molecule into a sedentary exercise replacement claim is an extrapolation that the primary literature does not support.

Reconstitution & handling

MOTS-c is supplied as a lyophilized white-to-off-white powder. Standard practice across the peptide literature is reconstitution in bacteriostatic water (0.9% benzyl alcohol) for short-term storage in solution, or in sterile water for injectionwhen the bacteriostatic preservative is undesirable for a given research design. Reconstituted MOTS-c is held at 2–8 °C and protected from light; like other peptides containing methionine and tryptophan residues, the molecule is susceptible to oxidative degradation, and avoiding repeated freeze–thaw cycles is standard practice. For longer-term storage, the lyophilized powder is held at −20 °C or below.

For background on what the analytical numbers on a peptide’s certificate of analysis actually mean — HPLC purity, mass-spectrometric identity confirmation, and water content for a peptide of this molecular weight — see our companion methods articles on what ≥99% purity actually means and how we verify peptide purity.

Further reading

The bibliography below points to the primary papers and reviews referenced in this profile. Where a single number is cited multiple times in the text, it indicates the same source supporting different statements rather than independent corroboration.